Growth in patients after allogeneic bone marrow transplant for hematological diseases in childhood

A. Cohen, M. T. Van-Lint, C. Uderzo, A. Rovelli, A. Lavagetto, V. Vitale, A. Morchio, A. Locasciulli, A. Bacigalupo, C. Romano

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The growth of 66 long-term survivors, transplanted in two centres (Genoa S. Martino and Monza) is reported. Patients were all under age 15 at the time of bone marrow transplantation (mean 9.8 ± 3.4 years; range 1.07-15 years) with a minimum follow-up of at least 12 months. They were divided into four groups. Group 1: eight patients with severe aplastic anemia (SAA); conditioning included cyclophosphamide (CY) 200 mg/kg only. Group 2: 32 patients with acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML); conditioning included CY 120 mg/kg and 10-12 Gy fractionated total body irradiation (fTBI). Group 3: 20 patients with ALL who had previously received cranial irradiation; conditioning included CY 120 mg/kg and fTBI with an additional testicular irradiation (4 Gy). Group 4: six patients with chronic myeloid leukemia (CML) and AML; conditioning included CY 200 mg/kg and busulfan (BU) 16 mg/kg. Growth was impaired in all four groups, including the unirradiated groups (-0.2 ± 0.7 and -0.5 ± 0.6 delta-SDS in groups 1 and 4, respectively). Growth impairment-SDS was statistically significant in the two irradiated groups (-0.7 ± 1.0 and -0.9 ± 1.0 delta-SDS in groups 2 and 3, respectively), more marked in patients who had had previous cranial irradiation. Chronic graft-versus-host disease and its treatment were not found to have a major effect on growth.

Original languageEnglish
Pages (from-to)343-348
Number of pages6
JournalBone Marrow Transplantation
Volume15
Issue number3
Publication statusPublished - 1995

Fingerprint

Hematologic Diseases
Bone Marrow
Transplants
Cyclophosphamide
Growth
Cranial Irradiation
Whole-Body Irradiation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Busulfan
Aplastic Anemia
Graft vs Host Disease
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone Marrow Transplantation
Survivors

Keywords

  • Childhood
  • Growth
  • Hematological disease
  • Transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Cohen, A., Van-Lint, M. T., Uderzo, C., Rovelli, A., Lavagetto, A., Vitale, V., ... Romano, C. (1995). Growth in patients after allogeneic bone marrow transplant for hematological diseases in childhood. Bone Marrow Transplantation, 15(3), 343-348.

Growth in patients after allogeneic bone marrow transplant for hematological diseases in childhood. / Cohen, A.; Van-Lint, M. T.; Uderzo, C.; Rovelli, A.; Lavagetto, A.; Vitale, V.; Morchio, A.; Locasciulli, A.; Bacigalupo, A.; Romano, C.

In: Bone Marrow Transplantation, Vol. 15, No. 3, 1995, p. 343-348.

Research output: Contribution to journalArticle

Cohen, A, Van-Lint, MT, Uderzo, C, Rovelli, A, Lavagetto, A, Vitale, V, Morchio, A, Locasciulli, A, Bacigalupo, A & Romano, C 1995, 'Growth in patients after allogeneic bone marrow transplant for hematological diseases in childhood', Bone Marrow Transplantation, vol. 15, no. 3, pp. 343-348.
Cohen, A. ; Van-Lint, M. T. ; Uderzo, C. ; Rovelli, A. ; Lavagetto, A. ; Vitale, V. ; Morchio, A. ; Locasciulli, A. ; Bacigalupo, A. ; Romano, C. / Growth in patients after allogeneic bone marrow transplant for hematological diseases in childhood. In: Bone Marrow Transplantation. 1995 ; Vol. 15, No. 3. pp. 343-348.
@article{f3285396919043e8a7e1e5f11f5beded,
title = "Growth in patients after allogeneic bone marrow transplant for hematological diseases in childhood",
abstract = "The growth of 66 long-term survivors, transplanted in two centres (Genoa S. Martino and Monza) is reported. Patients were all under age 15 at the time of bone marrow transplantation (mean 9.8 ± 3.4 years; range 1.07-15 years) with a minimum follow-up of at least 12 months. They were divided into four groups. Group 1: eight patients with severe aplastic anemia (SAA); conditioning included cyclophosphamide (CY) 200 mg/kg only. Group 2: 32 patients with acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML); conditioning included CY 120 mg/kg and 10-12 Gy fractionated total body irradiation (fTBI). Group 3: 20 patients with ALL who had previously received cranial irradiation; conditioning included CY 120 mg/kg and fTBI with an additional testicular irradiation (4 Gy). Group 4: six patients with chronic myeloid leukemia (CML) and AML; conditioning included CY 200 mg/kg and busulfan (BU) 16 mg/kg. Growth was impaired in all four groups, including the unirradiated groups (-0.2 ± 0.7 and -0.5 ± 0.6 delta-SDS in groups 1 and 4, respectively). Growth impairment-SDS was statistically significant in the two irradiated groups (-0.7 ± 1.0 and -0.9 ± 1.0 delta-SDS in groups 2 and 3, respectively), more marked in patients who had had previous cranial irradiation. Chronic graft-versus-host disease and its treatment were not found to have a major effect on growth.",
keywords = "Childhood, Growth, Hematological disease, Transplantation",
author = "A. Cohen and Van-Lint, {M. T.} and C. Uderzo and A. Rovelli and A. Lavagetto and V. Vitale and A. Morchio and A. Locasciulli and A. Bacigalupo and C. Romano",
year = "1995",
language = "English",
volume = "15",
pages = "343--348",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Growth in patients after allogeneic bone marrow transplant for hematological diseases in childhood

AU - Cohen, A.

AU - Van-Lint, M. T.

AU - Uderzo, C.

AU - Rovelli, A.

AU - Lavagetto, A.

AU - Vitale, V.

AU - Morchio, A.

AU - Locasciulli, A.

AU - Bacigalupo, A.

AU - Romano, C.

PY - 1995

Y1 - 1995

N2 - The growth of 66 long-term survivors, transplanted in two centres (Genoa S. Martino and Monza) is reported. Patients were all under age 15 at the time of bone marrow transplantation (mean 9.8 ± 3.4 years; range 1.07-15 years) with a minimum follow-up of at least 12 months. They were divided into four groups. Group 1: eight patients with severe aplastic anemia (SAA); conditioning included cyclophosphamide (CY) 200 mg/kg only. Group 2: 32 patients with acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML); conditioning included CY 120 mg/kg and 10-12 Gy fractionated total body irradiation (fTBI). Group 3: 20 patients with ALL who had previously received cranial irradiation; conditioning included CY 120 mg/kg and fTBI with an additional testicular irradiation (4 Gy). Group 4: six patients with chronic myeloid leukemia (CML) and AML; conditioning included CY 200 mg/kg and busulfan (BU) 16 mg/kg. Growth was impaired in all four groups, including the unirradiated groups (-0.2 ± 0.7 and -0.5 ± 0.6 delta-SDS in groups 1 and 4, respectively). Growth impairment-SDS was statistically significant in the two irradiated groups (-0.7 ± 1.0 and -0.9 ± 1.0 delta-SDS in groups 2 and 3, respectively), more marked in patients who had had previous cranial irradiation. Chronic graft-versus-host disease and its treatment were not found to have a major effect on growth.

AB - The growth of 66 long-term survivors, transplanted in two centres (Genoa S. Martino and Monza) is reported. Patients were all under age 15 at the time of bone marrow transplantation (mean 9.8 ± 3.4 years; range 1.07-15 years) with a minimum follow-up of at least 12 months. They were divided into four groups. Group 1: eight patients with severe aplastic anemia (SAA); conditioning included cyclophosphamide (CY) 200 mg/kg only. Group 2: 32 patients with acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML); conditioning included CY 120 mg/kg and 10-12 Gy fractionated total body irradiation (fTBI). Group 3: 20 patients with ALL who had previously received cranial irradiation; conditioning included CY 120 mg/kg and fTBI with an additional testicular irradiation (4 Gy). Group 4: six patients with chronic myeloid leukemia (CML) and AML; conditioning included CY 200 mg/kg and busulfan (BU) 16 mg/kg. Growth was impaired in all four groups, including the unirradiated groups (-0.2 ± 0.7 and -0.5 ± 0.6 delta-SDS in groups 1 and 4, respectively). Growth impairment-SDS was statistically significant in the two irradiated groups (-0.7 ± 1.0 and -0.9 ± 1.0 delta-SDS in groups 2 and 3, respectively), more marked in patients who had had previous cranial irradiation. Chronic graft-versus-host disease and its treatment were not found to have a major effect on growth.

KW - Childhood

KW - Growth

KW - Hematological disease

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=0028949461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028949461&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 343

EP - 348

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -